Biotech Stock News: NervGen Pharma (TSXV: NGEN) (OTCQX: NGENF) Receives Approval from Safety Review Committee to Proceed to Second Cohort in Multiple Ascending Dose Portion of Phase 1 Clinical Trial of NVG-291


Vancouver, British Columbia – March 15, 2022 (Newsfile Corp.) ( Newswire) NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has received approval from the Safety Review Committee to advance to the second cohort in the multiple ascending dose portion of its Phase 1 clinical trial of the Company’s proprietary lead compound, NVG-291.

The Wall Street Journal: California bill would hold tech companies liable for kids’ social-media addiction

Previous article

AI Eye Podcast 670: Stocks discussed: (OTCPINK: $GTCH) (NYSE: $ACN) (NYSE: $EC) (NasdaqGS: $AMZN)

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News